Markets & Investing
Why Do We Need a Women In Psychedelics Network?: Mindshifting Moments #11
Najla Guthrie, the Founder of the Women in Psychedelics Network joins host Margaret Williamson in this important conversation about equity, equality, and…
Najla Guthrie, the Founder of the Women in Psychedelics Network joins host Margaret Williamson in this important conversation about equity, equality, and empowerment.
As the psychedelics industry continues to grow, it’s important that we identify opportunities for everyone. During this conversation, the pair emphasizes the importance of women in the board room and how that crucial sentiment holds true across all characteristics, attributes, and groups of people.
How Can We Lift Women Up?
The psychedelics industry, or any nascent industry for that matter, has a real opportunity to completely change how we look at power, control, and equity. With new technologies, the right policies, and true empowerment, this industry is well-positioned to influence others about “how it could be.”
To accomplish this, though, it requires the right intentions. Organizations must establish guard rails, encourage open-mindedness, celebrate a wide breadth of opinions and beliefs, and execute.
At Psychedelic Invest, we’re excited to embrace positive change and will continue to lift up every woman that deserves more and better opportunities.
Transcription
The transcription will be available after the event.
-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics6 days ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics6 days ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics1 week ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics1 week ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?